Cargando…

Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience

Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to partici...

Descripción completa

Detalles Bibliográficos
Autores principales: Persano, Irene, Cani, Massimiliano, Del Rio, Benedetta, Ferrari, Giorgia, Garbo, Edoardo, Parlagreco, Elena, Pisano, Chiara, Cetoretta, Valeria, Delcuratolo, Marco Donatello, Turco, Fabio, Audisio, Alessandro, Cecchi, Cristina, Leone, Gianmarco, Napoli, Valerio Maria, Bertaglia, Valentina, Bianco, Valentina, Capelletto, Enrica, D’Amiano, Carmen, Di Maio, Massimo, Gianetta, Martina, Novello, Silvia, Passiglia, Francesco, Scagliotti, Giorgio Vittorio, Bironzo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855735/
https://www.ncbi.nlm.nih.gov/pubmed/36672673
http://dx.doi.org/10.3390/biomedicines11010165
_version_ 1784873448407826432
author Persano, Irene
Cani, Massimiliano
Del Rio, Benedetta
Ferrari, Giorgia
Garbo, Edoardo
Parlagreco, Elena
Pisano, Chiara
Cetoretta, Valeria
Delcuratolo, Marco Donatello
Turco, Fabio
Audisio, Alessandro
Cecchi, Cristina
Leone, Gianmarco
Napoli, Valerio Maria
Bertaglia, Valentina
Bianco, Valentina
Capelletto, Enrica
D’Amiano, Carmen
Di Maio, Massimo
Gianetta, Martina
Novello, Silvia
Passiglia, Francesco
Scagliotti, Giorgio Vittorio
Bironzo, Paolo
author_facet Persano, Irene
Cani, Massimiliano
Del Rio, Benedetta
Ferrari, Giorgia
Garbo, Edoardo
Parlagreco, Elena
Pisano, Chiara
Cetoretta, Valeria
Delcuratolo, Marco Donatello
Turco, Fabio
Audisio, Alessandro
Cecchi, Cristina
Leone, Gianmarco
Napoli, Valerio Maria
Bertaglia, Valentina
Bianco, Valentina
Capelletto, Enrica
D’Amiano, Carmen
Di Maio, Massimo
Gianetta, Martina
Novello, Silvia
Passiglia, Francesco
Scagliotti, Giorgio Vittorio
Bironzo, Paolo
author_sort Persano, Irene
collection PubMed
description Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life.
format Online
Article
Text
id pubmed-9855735
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98557352023-01-21 Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience Persano, Irene Cani, Massimiliano Del Rio, Benedetta Ferrari, Giorgia Garbo, Edoardo Parlagreco, Elena Pisano, Chiara Cetoretta, Valeria Delcuratolo, Marco Donatello Turco, Fabio Audisio, Alessandro Cecchi, Cristina Leone, Gianmarco Napoli, Valerio Maria Bertaglia, Valentina Bianco, Valentina Capelletto, Enrica D’Amiano, Carmen Di Maio, Massimo Gianetta, Martina Novello, Silvia Passiglia, Francesco Scagliotti, Giorgio Vittorio Bironzo, Paolo Biomedicines Article Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life. MDPI 2023-01-09 /pmc/articles/PMC9855735/ /pubmed/36672673 http://dx.doi.org/10.3390/biomedicines11010165 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Persano, Irene
Cani, Massimiliano
Del Rio, Benedetta
Ferrari, Giorgia
Garbo, Edoardo
Parlagreco, Elena
Pisano, Chiara
Cetoretta, Valeria
Delcuratolo, Marco Donatello
Turco, Fabio
Audisio, Alessandro
Cecchi, Cristina
Leone, Gianmarco
Napoli, Valerio Maria
Bertaglia, Valentina
Bianco, Valentina
Capelletto, Enrica
D’Amiano, Carmen
Di Maio, Massimo
Gianetta, Martina
Novello, Silvia
Passiglia, Francesco
Scagliotti, Giorgio Vittorio
Bironzo, Paolo
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
title Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
title_full Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
title_fullStr Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
title_full_unstemmed Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
title_short Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
title_sort short-term safety and psychosocial impact of the bnt162b2 mrna covid-19 vaccine in cancer patients—an italian single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855735/
https://www.ncbi.nlm.nih.gov/pubmed/36672673
http://dx.doi.org/10.3390/biomedicines11010165
work_keys_str_mv AT persanoirene shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT canimassimiliano shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT delriobenedetta shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT ferrarigiorgia shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT garboedoardo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT parlagrecoelena shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT pisanochiara shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT cetorettavaleria shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT delcuratolomarcodonatello shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT turcofabio shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT audisioalessandro shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT cecchicristina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT leonegianmarco shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT napolivaleriomaria shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT bertagliavalentina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT biancovalentina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT capellettoenrica shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT damianocarmen shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT dimaiomassimo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT gianettamartina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT novellosilvia shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT passigliafrancesco shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT scagliottigiorgiovittorio shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience
AT bironzopaolo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience